Ultragenyx Pharmaceutical (NASDAQ: RARE) has announced that it will be releasing its financial results for the third quarter of 2024 on Tuesday 5th November 2024. The report will be made available after market close, allowing investors and analysts to evaluate the company's performance during this period.
According to the predictions of financial experts on Wall Street, the business is expected to announce an anticipated $1.45 loss per share for the quarter. Further, the firm is poised to disclose a total revenue of $135.79 million for the period.
The company's earnings report for the corresponding quarter of the previous year showcased a per-share loss of $2.23. This notable figure was achieved due to the company's impressive total revenue of $98.05 million recorded during that specific period.
The company's yearly performance has been analyzed by Wall Street analysts, who have projected a total revenue of $536.8 million. Moreover, they anticipate the company to disclose loss of $6.32 per share for the fiscal year.
Additionally, The company will host a conference call with investors and analysts on 5th November 2024 at 05:00 PM eastern time to review the Q3 2024 financial results.
Ultragenyx Pharmaceutical (RARE) closed Friday's regular trading session at $50.99, reflecting a 0.00 percent , with a volume of 650.80 thousand shares.
